期刊文献+

国产去甲长春碱与卡铂联合治疗老年非小细胞肺癌疗效观察 被引量:2

原文传递
导出
摘要 目的观察国产去甲长春碱(NVB)与卡铂(CBP)联合方案(NC方案)治疗老年中晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法NVB25mg/m2加入0.9%生理盐水150ml,15min静脉滴注,第1,8天,并于滴注前、后各静脉冲入地塞米松5mg;CBP300mg/m2加5%葡萄糖注射液500ml静脉滴入3h,第1天或第2天,化疗前常规应用盐酸格雷司琼止吐,化疗后每隔2d复查血常规1次。结果该组24例,总有效率为41.7%,初治病例有效率为45.0%,复治病例为25.0%。毒副反应主要为骨髓抑制,发生率为100%。其中Ⅲ~Ⅳ度骨髓抑制发生率为21.0%,经用粒细胞集落刺激因子(G-CSF)治疗及对症治疗后恢复。29.0%的患者出现血小板减少,均在Ⅰ~Ⅱ度之间,未出现Ⅲ度血小板下降,化疗未受影响。结论NC方案安全可靠,毒副反应比较轻,可以作为老年NSCLC一线可选择的方案。
作者 刘萍
出处 《肿瘤研究与临床》 CAS 2006年第5期339-340,共2页 Cancer Research and Clinic
  • 相关文献

参考文献3

二级参考文献28

  • 1[1]Fry W, Phillips, Menck H. Ten-year survey of lung cancer treatment and survival in hospitals in United States. Cancer,1999, 86:1867
  • 2[2]Socinski M. Chemotherapy for stage Ⅳ non-small cell lung cancer: An evidence-based guide for the practicing clinican. Philadelphia: WB Saunders Company, 2001, 307
  • 3[3]Ng R, Boer RD, Park A, et al. Non small cell lung cancer(NSCLC): Are elderly patients being under-treated? ASCO Pro,2004, 7118
  • 4[4]Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage ⅢB or Ⅳ nonsmall cell lung carcinoma triated with carboplatin and paclitaxel. Cancer, 2003, 98(4) :779
  • 5[5]Lebitasy MP, Monnet L, Depierre A, et al. Management of elderly lung cancer patients in France: A national prospective survey by the French intergroup of thoracic oncology (WCT).ASCO Pro, 2004, 8163
  • 6[6]Okamoto H, Kudoh H, Nagatomo A, et al. A combination chemotherapy of carboplatin and irinotecan in elderly patients with small cell lung cancer (SCLC). ASCO Pro, 2004, 7212
  • 7[7]FukudaM, Oka M, SoejimaY, etal. Elderly (≥70)smallcell lung cancer (SCLC) chemotherapy: A phase Ⅰ study of carboplatin (CBDCA) and etoposide (VP-16). ASCO Pro,2004, 7217
  • 8[8]Katz AV, Arruda MT, Yamaguchi JY, et al. Comparative retrospective study between brs supportive care (BSC) versus chemotherapy for elderly patients with NSCLC. ASCO Pro, 2004,7355
  • 9[9]Yau T, Asley S, Smith L, et al. Time and chemotherapy treatments trends in the elderly (age 》 70) with lung cancer in a single UK cancer centre. ASCO Pro, 2004, 7128
  • 10[10]The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with adbanced non-small-cell lung cancer. J Natl Cancer Inst,1999, 91:66

共引文献50

同被引文献14

  • 1潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 2Pallis AG,Gridelli C,Van Meerbeeck JP,et al.EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.Ann Oncol,2010,21:692-706.
  • 3Davidoff AJ,Tang M,Seal B,et al.Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.J Clin Oncol,2010,28:2191-2197.
  • 4World Health Organisation WHO Offset publication No 48.WHO Handbook for Reporting Results of Cancer Treatment.Geneva:WHO,1979.
  • 5Gridelli C,Maione P,Rossi A,et al.Treatment of advanced non-smallcell lung cancer in the elderly.Lung Cancer,2009,66:282-286.
  • 6Quoix EA,Oster J,Westeel V,et al.Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89:IFCT-0501 randomized phase Ⅲ study in advanced non-small cell lung cancer (NSCLC).J Clin Oncol,2010,28:18.
  • 7Blanchard EM,Moon J,Hesketh PJ,et al.Comparison of platinumbased chemotherapy in patients older and younger than 70 years:an analysis of southwest oncology group trials 9308 and 9509.J Thorac Oncol,2011,6:115-120.
  • 8Kawaguchi T,Takada M,Kubo A,et al.Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer.a comprehensive analysis of 26,957 patients with NSCLC.J Thorac Oncol,2010,5:620-630.
  • 9Hoang T,Xu R,Schiller JH,et al.Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.J Clin Oncol,2005,23:175-183.
  • 10Favaretto AG,Pasello G,Magro C.Second and third line treatment in advanced non-small cell lung cancer.Discov Med,2009,8:204-209.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部